allora...si fa interessante CTIC....
Una buona notizia a riguardo...........
Roche and The University of Vermont Grant Cell Therapeutics, Inc. (CTI) Exclusive Worldwide License to a New Class of Anticancer Compounds
Bisplatinum Agents Are First New Class of Platinum Complexes Scheduled to Enter Human Testing in 2006
SEATTLE, Dec 15, 2004 /PRNewswire-FirstCall via COMTEX/ -- The University of Vermont, and Cell Therapeutics Europe S.r.l., a subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC), have entered into an exclusive worldwide, royalty-bearing license to a new class of platinum-containing, anticancer drug candidates, called bisplatinum compounds. Under the terms of the agreement, CTI has development and commercialization rights to the compounds. At the same time, Roche has granted CTI a worldwide license for bisplatinum compounds under its patents. Both agreements foresee certain milestone payments and royalties on future sales of the drugs.
"Bisplatinum compounds are part of an important class of anticancer agents known as platinates, currently used as standard treatment for lung, ovarian and colorectal cancer, among others. Our development group is working diligently to advance an investigational drug candidate in 2005, so we can begin testing the bisplatinum compounds in humans by 2006," stated Silvano Spinelli, EVP of Development at CTI.
Though, currently marketed platinum drugs are standard of care in the treatment of many common cancers, patients often develop resistance to them, limiting their overall clinical benefit. In contrast to standard platinum agents, which contain a single platinum molecule, bisplatinum compounds contain two platinum molecules which may help to stem tumor resistance to platinum. It is generally believed that standard platinum agents fight tumors by binding between DNA, a mechanism known as intermolecular binding. With two platinum molecules, bisplatinum compounds cause two different types of binding, intermolecular -- binding between the DNA strand, and intramolecular -- binding within the DNA strand. CTI will study this double-binding effect to see if bisplatinum compounds can prevent resistance and produce a more effective therapy.
appena ne avranno incastrati un bel po'........
... pensi sia il caso di comprare qualcosa ? 
